UCM have some great technology and good management.
I like that they keep the market informed of their progress and that they are looking to influence decision makers by supporting studies. They also keep tight reigns of their $$$ with minimal spending and have very few tradeable shares on issue.
Sales have been pretty dissapointing though - hence the downward chart. Most sales seem to be going to the distributers themselves, however a few have ended up in hospitals. The sell-off of one of the seed investors was also a concern.
I have UCM on my watchlist. It'll be interesting to see how they fare once they receive FDA approval.
I don't hold UCM, but will consider if sales improve. UCM are the only other Biotech I would put my $$$ into - the other being PXS.
